Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: WSR001
MIFTS: 19

Was-Related Disorders

Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Was-Related Disorders

About this section

MalaCards integrated aliases for Was-Related Disorders:

Name: Was-Related Disorders 25

Characteristics:

GeneReviews:

25
Penetrance Penetrance is complete in males with a was pathogenic variant.
Sources

Summaries for Was-Related Disorders

About this section
MalaCards based summary : Was-Related Disorders is related to wiskott-aldrich syndrome and autoimmune disease. An important gene associated with Was-Related Disorders is WAS (WASP Actin Nucleation Promoting Factor). The drugs Amantadine and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and endothelial.

GeneReviews: NBK1178
Sources

Related Diseases for Was-Related Disorders

About this section

Diseases related to Was-Related Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 wiskott-aldrich syndrome 11.2
2 autoimmune disease 9.8
3 severe congenital neutropenia 9.8
4 neutropenia 9.8
5 thrombocytopenia 9.8
6 dermatitis 9.8
7 purpura 9.8
8 hemolytic anemia 9.8

Graphical network of the top 20 diseases related to Was-Related Disorders:



Diseases related to Was-Related Disorders
Sources

Symptoms & Phenotypes for Was-Related Disorders

About this section
Sources

Drugs & Therapeutics for Was-Related Disorders

About this section

Drugs for Was-Related Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 281)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amantadine Approved Phase 4 768-94-5 2130
2
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Desipramine Approved, Investigational Phase 4 50-47-5 2995
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
7
Molindone Approved Phase 4 7416-34-4 23897
8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
9
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
10
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
11
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
12
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
13
Raclopride Investigational Phase 4 84225-95-6
14 Adrenergic Agonists Phase 4
15 Adrenergic alpha-Agonists Phase 4
16 Anti-Arrhythmia Agents Phase 4
17 Central Nervous System Stimulants Phase 4
18 Quetiapine Fumarate Phase 4 111974-72-2
19 Antiparkinson Agents Phase 4
20 Sodium Channel Blockers Phase 4
21 Hypnotics and Sedatives Phase 4
22 Diuretics, Potassium Sparing Phase 4
23 Anesthetics, Intravenous Phase 4
24 Anesthetics, General Phase 4
25 Antidepressive Agents, Tricyclic Phase 4
26 interferons Phase 4
27 Antipsychotic Agents Phase 4
28 Dopamine Antagonists Phase 4
29 Gastrointestinal Agents Phase 4
30 Antiemetics Phase 4
31 Serotonin Uptake Inhibitors Phase 4
32 Psychotropic Drugs Phase 4
33 Anti-Anxiety Agents Phase 4
34 Anticonvulsants Phase 4
35 Hormones Phase 4
36 Calcium, Dietary Phase 4
37 calcium channel blockers Phase 4
38
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
39
Calcium Nutraceutical Phase 4 7440-70-2 271
40
Propranolol Approved, Investigational Phase 3 525-66-6 4946
41
Lofexidine Approved, Investigational Phase 3 31036-80-3 30668
42
Norepinephrine Approved Phase 2, Phase 3 51-41-2 439260
43
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 26757 5195
44
Biperiden Approved, Investigational Phase 2, Phase 3 514-65-8 2381
45
Nicotinamide Approved, Investigational Phase 2, Phase 3 98-92-0 936
46
Mineral oil Approved, Vet_approved Phase 2, Phase 3 8042-47-5
47
Tocopherol Approved, Investigational Phase 2, Phase 3 1406-66-2
48
Methadone Approved Phase 3 76-99-3 4095
49
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
50
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-02-9 14985

Interventional clinical trials:

(show top 50) (show all 646)
# Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse, Part 1 Unknown status NCT00000346 Phase 4
2 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
3 Comparison Between Dexmedetomidine and Lidocaine as an Adjuvant to General Anesthesia in Patients Undergoing Major Abdominal Surgeries Unknown status NCT03600493 Phase 4 Dexmedetomidine;Lidocaine
4 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
5 Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence Completed NCT00232336 Phase 4 quetiapine
6 Methylphenidate Raclopride PET Test Completed NCT00015301 Phase 4 Methylphenidate
7 Modeling Impaired Judgement in Cocaine Abusers Completed NCT00015236 Phase 4
8 Brain Changes in Stimulant Dependent Subjects Completed NCT00000343 Phase 4
9 Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients Completed NCT01471145 Phase 4 Naltrexone
10 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4 Dexmedetomidine;Lidocaine;Fentanyl
11 Evaluation of Preference for a Buprenorphine-based Maintenance Therapy, After a Switch From Buprenorphine Alone (Subutex®) to the Buprenorphine/Naloxone Combination (Suboxone®), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
12 Methamphetamine Abuse Pharmacology in Patients With AIDS Completed NCT00000321 Phase 4 Desipramine
13 Feasibility Study of Take-Home LAAM Medication Completed NCT00000300 Phase 4 LAAM
14 Assessment of Hepatic Function in Alcoholic Patients Administered Therapeutic Dosing of Acetaminophen- a Multicenter Study Completed NCT00402571 Phase 4 acetaminophen
15 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
16 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence Completed NCT00015275 Phase 4
17 Abuse Liability of Controlled-Release Oxycodone Formulations Completed NCT02101840 Phase 4 Apo-Oxycodone CR®;OxyNEO®;Placebo
18 Hepatic Function Following Five Days of Therapeutic Dosing of Acetaminophen in Alcoholics Completed NCT00427206 Phase 4 acetaminophen (4g/day);placebo
19 Starting Treatment With Agonist Replacement Therapies (START) Completed NCT00315341 Phase 4 Buprenorphine/naloxone;Methadone
20 Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks Completed NCT00194480 Phase 4 Pegylated Interferon
21 Pharmacotherapy and Intensive Treatment Completed NCT00000218 Phase 4 Carbamazepine
22 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
23 VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
24 Drug Contextual Conditioning With in Humans: Causes and Consequences Completed NCT03075501 Phase 4 Stimulant or sedative;Placebo
25 A Feasibility Study for Testing the Effects of Extended-release Naltrexone (Vivitrol) on Recidivism and Other Participant Outcomes in Drug Court Settings Completed NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
26 Treatment of Schizophrenia and Related Disorders in Children and Adolescents Completed NCT00053703 Phase 4 Risperidone;Olanzapine (enrollment closed in this treatment);Molindone
27 "Re-examining Maintenance Antipsychotic Treatment in Schizophrenia: "Extended" Antipsychotic Dosing" Not yet recruiting NCT04478838 Phase 4 Risperidone;Olanzapine
28 A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Structured Opioid Discontinuation Versus Continued Opioid Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioid Analgesic Therapy for Chronic Pain. Terminated NCT02741076 Phase 4 Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER);Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
29 Evaluation of Pregabalin's Abuse Liability and Its Effects on Benzodiazepine Withdrawal Symptoms in Inpatients Undergoing Medically Assisted Benzodiazepine Withdrawal Terminated NCT02423018 Phase 4 Pregabalin;Placebo
30 Brain Imaging: Cocaine Effects & Medication Development Withdrawn NCT00000270 Phase 4 Cocaine
31 Medication Development for Cocaine Dependence Unknown status NCT00249691 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
32 Using Reconsolidation Blockade to Treat Trauma Related Disorders After Paris Attacks: an Effectiveness Study Unknown status NCT02789982 Phase 3 β-adrenergic blocker propranolol
33 Naltrexone and CBT for Problem-drinking MSM Completed NCT00444418 Phase 3 Naltrexone
34 Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial of At-Home Versus In-Office Buprenorphine Induction Completed NCT00684554 Phase 2, Phase 3 Buprenorphine
35 Voucher-Based Incentives in a Prevention Setting Completed NCT00607269 Phase 2, Phase 3
36 Adolescent Drug and HIV Prevention in South Africa Completed NCT00336180 Phase 2, Phase 3
37 CBT And Venlafaxine Treatments For Anxiety In Alcoholism Completed NCT00248612 Phase 2, Phase 3 Venlafaxine
38 Motivational Enhancement for Spanish Speaking Individuals Completed NCT00078169 Phase 3
39 Women's Treatment for Trauma and Substance Use Disorders Completed NCT00078156 Phase 3
40 Telephone Enhancement Procedure (TELE) for Continuing Care Completed NCT00067171 Phase 3
41 Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics Completed NCT00033007 Phase 3
42 Motivational Interviewing (MI) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse Completed NCT00032994 Phase 3
43 Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence Completed NCT00032929 Phase 3 Selegiline
44 Combining Behavioral Treatment With Agonist Maintenance Completed NCT00000311 Phase 3 Buprenorphine;methadone
45 Effect of Nefazodone on Relapse in Females With Cocaine Abuse Completed NCT00000293 Phase 3 Nefazodone
46 Maternal Opioid Treatment: Human Experimental Research Completed NCT00271219 Phase 3 Methadone;Buprenorphine
47 Job Seekers Training for Patients With Drug Dependence Completed NCT00102362 Phase 3
48 Multicenter Clinical Trial of Buprenorphine Completed NCT00000207 Phase 3 Buprenorphine
49 A Randomized, Blinded, Active-controlled Non-inferiority Study of the Efficacy and Safety of OX219 for the Induction of Treatment of Opioid Dependence Completed NCT01848054 Phase 3 Buprenorphine/naloxone sublingual tablets;Buprenorphine
50 Buprenorphine Group Medical Visits for Drug Users at Risk for HIV Completed NCT02526212 Phase 3 Buprenorphine

Search NIH Clinical Center for Was-Related Disorders

Sources

Genetic Tests for Was-Related Disorders

About this section
Sources

Anatomical Context for Was-Related Disorders

About this section

MalaCards organs/tissues related to Was-Related Disorders:

40
Liver, Brain, Endothelial, Pituitary, Bone Marrow, Myeloid
Sources

Publications for Was-Related Disorders

About this section

Articles related to Was-Related Disorders:

(show top 50) (show all 66)
# Title Authors PMID Year
1
The clinical features of autoimmunity in 53 patients with Wiskott-Aldrich syndrome in China: a single-center study. 25
25877044 2015
2
Wiskott-Aldrich syndrome/X-linked thrombocytopenia in China: Clinical characteristic and genotype-phenotype correlation. 25
25931402 2015
3
In vivo reversion of an inherited mutation in a Chinese patient with Wiskott-Aldrich syndrome. 25
25862925 2015
4
Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. 25
25898053 2015
5
Wiskott-Aldrich syndrome in a girl caused by heterozygous WASP mutation and extremely skewed X-chromosome inactivation: a novel association with maternal uniparental isodisomy 6. 25
25633059 2015
6
Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. 25
24817816 2014
7
Pathogenic mechanisms and clinical implications of congenital neutropenia syndromes. 25
24145314 2013
8
Combined de-novo mutation and non-random X-chromosome inactivation causing Wiskott-Aldrich syndrome in a female with thrombocytopenia. 25
23943155 2013
9
Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. 25
23845947 2013
10
X-linked thrombocytopenia in a female with a complex familial pattern of X-chromosome inactivation. 25
23689198 2013
11
Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome. 25
23264593 2013
12
Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome. 25
22426750 2012
13
Autoimmunity in wiskott-Aldrich syndrome: an unsolved enigma. 25
22826711 2012
14
A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. 25
22231303 2012
15
Monozygotic twin pair showing discordant phenotype for X-linked thrombocytopenia and Wiskott-Aldrich syndrome: a role for epigenetics? 25
21710275 2011
16
Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. 25
21659547 2011
17
Genetic etiologies of severe congenital neutropenia. 25
21206270 2011
18
Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome. 25
21076297 2011
19
Stem-cell gene therapy for the Wiskott-Aldrich syndrome. 25
21067383 2010
20
X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. 25
20173115 2010
21
Progress and prospects: gene therapy for inherited immunodeficiencies. 25
19776764 2009
22
G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. 25
19794089 2009
23
Revertant somatic mosaicism in the Wiskott-Aldrich syndrome. 25
19129986 2009
24
Results and long-term outcome in 39 patients with Wiskott-Aldrich syndrome transplanted from HLA-matched and -mismatched donors. 25
18846321 2009
25
Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. 25
17901250 2008
26
Detection of 28 novel mutations in the Wiskott-Aldrich syndrome and X-linked thrombocytopenia based on multiplex PCR. 25
17400488 2007
27
Stem cell transplantation for the Wiskott-Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation. 25
17013426 2006
28
WIP and WASP play complementary roles in T cell homing and chemotaxis to SDF-1alpha. 25
16141245 2006
29
An electrostatic steering mechanism of Cdc42 recognition by Wiskott-Aldrich syndrome proteins. 25
16246732 2005
30
Genotype-proteotype linkage in the Wiskott-Aldrich syndrome. 25
16002738 2005
31
WASP deficiency leads to global defects of directed leukocyte migration in vitro and in vivo. 25
15774550 2005
32
Impaired dendritic-cell homing in vivo in the absence of Wiskott-Aldrich syndrome protein. 25
15494425 2005
33
Mutations of the Wiskott-Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. 25
15284122 2004
34
Regulation of WASP/WAVE proteins: making a long story short. 25
15452139 2004
35
Regulation of actin dynamics by WASP and WAVE family proteins. 25
15183187 2004
36
Fyn and PTP-PEST-mediated regulation of Wiskott-Aldrich syndrome protein (WASp) tyrosine phosphorylation is required for coupling T cell antigen receptor engagement to WASp effector function and T cell activation. 25
14707117 2004
37
Clinical course of patients with WASP gene mutations. 25
12969986 2004
38
An international study examining therapeutic options used in treatment of Wiskott-Aldrich syndrome. 25
14697741 2003
39
WASP (Wiskott-Aldrich syndrome protein) gene mutations and phenotype. 25
14612666 2003
40
Wiskott-Aldrich syndrome in a female with skewed X-chromosome inactivation. 25
14636648 2003
41
Wiskott-Aldrich Syndrome: a model for defective actin reorganization, cell trafficking and synapse formation. 25
14499269 2003
42
Autoimmunity in Wiskott-Aldrich syndrome. 25
12819473 2003
43
Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. 25
12728121 2003
44
Second-site mutation in the Wiskott-Aldrich syndrome (WAS) protein gene causes somatic mosaicism in two WAS siblings. 25
12727931 2003
45
Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. 25
12433691 2003
46
Wiskott-Aldrich syndrome in a female. 25
12351383 2002
47
X-linked thrombocytopenia in a girl. 25
12199801 2002
48
Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. 25
12177428 2002
49
Somatic mosaicism in Wiskott--Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. 25
11447283 2001
50
Spontaneous in vivo reversion of an inherited mutation in the Wiskott-Aldrich syndrome. 25
11290809 2001
Sources

Variations for Was-Related Disorders

About this section
Sources

Expression for Was-Related Disorders

About this section
Search GEO for disease gene expression data for Was-Related Disorders.
Sources

Pathways for Was-Related Disorders

About this section
Sources

GO Terms for Was-Related Disorders

About this section
Sources

Sources for Was-Related Disorders

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....